Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-29T07:54:27.504Z Has data issue: false hasContentIssue false
  • English
  • Français

Beyond the threshold

Published online by Cambridge University Press:  04 April 2016

Anthony H. Harris
Anthony H. Harris*
Affiliation:
Centre for Health Economics, Monash Business School, Monash University, Clayton, Victoria 3800, Australia
*
* Correspondence to: Anthony Harris, Centre for Health Economics, 15 Innovation Walk Monash University, Clayton, Victoria, 3800, Australia. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Debate
Information
Health Economics, Policy and Law , Volume 11 , Issue 4 , October 2016 , pp. 433 - 438
Check for updates
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Australian Government (2015a), ‘Public summary document: sofosbuvir’. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2015-03/Files/sofosbuvir-psd-march-2015.pdf [21 December 2015].Google Scholar
Australian Government (2015b), ‘Turnbull Government invests over $1B to cure Hep C’. https://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2015-ley154.htm?OpenDocument&yr=2015&mth=12 [21 December 2015].Google Scholar
Claxton, K., Briggs, A., Buxton, M. J., Culyer, A. J., McCabe, C., Walker, S. and Sculpher, M. J. (2008), ‘Value based pricing for NHS drugs: an opportunity not to be missed?’, BMJ, 336(7638): 251–254.Google Scholar
Eckermann, S. and Pekarsky, B. (2014), ‘Can the real opportunity cost stand up: displaced services, the straw man outside the room’, Pharmacoeconomics, 32(4): 319–325.Google Scholar
Gafni, A. and Birch, S. (2003), ‘NICE methodological guidelines and decision making in the national health service in England and Wales’, Pharmacoeconomics, 21(3): 149–157.Google Scholar
Gafni, A. and Birch, S. (2006), ‘Incremental cost-effectiveness ratios (ICERs): the silence of the lambda’, Social Science & Medicine, 62(9): 2091–2100.Google Scholar
Haas, M., Hall, J., Viney, R. and Gallego, G. (2012), ‘Breaking up is hard to do: why disinvestment in medical technology is harder than investment’, Australian Health Review, 36(2): 148–152.Google Scholar
Ham, C. and Coulter, A. (2001), ‘Explicit and implicit rationing: taking responsibility and avoiding blame for health care choices’, Health Services Research & Policy, 6(3): 163–169.Google Scholar
Harris, A., Li, J. and Yong, K. (2015), ‘What can we expect from value-based funding of medicines? A retrospective study’, Pharmacoeconomics, 1–10, doi:10.1007/s40273-015-0354-z.Google Scholar
Harris, A. H., Hill, S. R., Chin, G., Ling, J. J. and Walkom, E. (2008), ‘The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004’, Medical Decision Making, 28: 713–722.Google Scholar
PHARMAC (2015), ‘Fact sheet #5: medicines and medical devices contract negotiation’, New Zealand: New Zealand Government.Google Scholar
Richardson, J. and McKie, J. (2007), ‘Economic evaluation of services for a National Health Scheme: the case for a fairness-based framework’, Journal of Health Economics, 26(4): 785–799.Google Scholar
Weinstein, M. C. (2012), ‘Decision Rules for Incremental Cost-Effectiveness Analysis’, in A. M. Jones (ed.), The Elgar Companion to Health Economics, 2nd edn, Cheltenham: Edward Elgar Publishing, Inc., 505–514.Google Scholar
Weinstein, M. C. and Stason, W. B. (1977), ‘Foundations of cost-effectiveness analysis for health and medical practices’, New England Journal of Medicine, 296(13): 716–721.Google Scholar